BRPI0922736A2 - sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno - Google Patents

sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Info

Publication number
BRPI0922736A2
BRPI0922736A2 BRPI0922736A BRPI0922736A BRPI0922736A2 BR PI0922736 A2 BRPI0922736 A2 BR PI0922736A2 BR PI0922736 A BRPI0922736 A BR PI0922736A BR PI0922736 A BRPI0922736 A BR PI0922736A BR PI0922736 A2 BRPI0922736 A2 BR PI0922736A2
Authority
BR
Brazil
Prior art keywords
ehptacosa
tetracyclo
triaza
dioxin
decene
Prior art date
Application number
BRPI0922736A
Other languages
English (en)
Inventor
Deodaunia William Anthony
Dymock Bryan
Hsia Angeline Lee Cheng
Original Assignee
Sstarbio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sstarbio Pte Ltd filed Critical Sstarbio Pte Ltd
Publication of BRPI0922736A2 publication Critical patent/BRPI0922736A2/pt
Publication of BRPI0922736A8 publication Critical patent/BRPI0922736A8/pt
Publication of BRPI0922736B1 publication Critical patent/BRPI0922736B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22Tricarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D201/00Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02Preparation of lactams
    • C07D201/10Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
BRPI0922736-9A 2008-12-11 2009-12-09 Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste BRPI0922736B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121.668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (3)

Publication Number Publication Date
BRPI0922736A2 true BRPI0922736A2 (pt) 2017-10-31
BRPI0922736A8 BRPI0922736A8 (pt) 2021-11-09
BRPI0922736B1 BRPI0922736B1 (pt) 2022-02-22

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922736-9A BRPI0922736B1 (pt) 2008-12-11 2009-12-09 Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste

Country Status (23)

Country Link
US (2) US8980873B2 (pt)
EP (1) EP2376499B1 (pt)
JP (1) JP5669748B2 (pt)
KR (1) KR101729918B1 (pt)
CN (1) CN102282148B (pt)
AR (2) AR074724A1 (pt)
AU (1) AU2009325147B2 (pt)
BR (1) BRPI0922736B1 (pt)
CA (1) CA2746058C (pt)
DK (1) DK2376499T3 (pt)
ES (1) ES2536558T3 (pt)
HR (1) HRP20150428T1 (pt)
IL (3) IL213418A0 (pt)
MX (1) MX2011006206A (pt)
MY (1) MY160005A (pt)
NZ (1) NZ593223A (pt)
PL (1) PL2376499T3 (pt)
PT (1) PT2376499E (pt)
RU (1) RU2527970C2 (pt)
SG (1) SG171907A1 (pt)
TW (1) TWI449705B (pt)
WO (1) WO2010068181A1 (pt)
ZA (1) ZA201104032B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536558T3 (es) 2008-12-11 2015-05-26 Cti Biopharma Corp. Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno
US8987243B2 (en) * 2008-12-11 2015-03-24 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
KR101673979B1 (ko) 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
EE200300557A (et) * 2001-05-14 2004-04-15 Pfizer Products Inc. 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
AU2002341327A1 (en) * 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
AU2006316072B2 (en) 2005-11-16 2011-12-22 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
ES2536558T3 (es) 2008-12-11 2015-05-26 Cti Biopharma Corp. Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno

Also Published As

Publication number Publication date
CN102282148A (zh) 2011-12-14
EP2376499B1 (en) 2015-02-25
RU2011126173A (ru) 2013-01-20
WO2010068181A8 (en) 2011-08-18
IL289379A (en) 2022-02-01
PT2376499E (pt) 2015-06-03
JP2012511571A (ja) 2012-05-24
TWI449705B (zh) 2014-08-21
ES2536558T3 (es) 2015-05-26
MY160005A (en) 2017-02-15
IL250310A0 (en) 2017-03-30
CA2746058A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
AU2009325147B2 (en) 2014-08-14
KR20110106344A (ko) 2011-09-28
ZA201104032B (en) 2012-08-29
US20110294831A1 (en) 2011-12-01
US8980873B2 (en) 2015-03-17
NZ593223A (en) 2013-08-30
HK1161877A1 (en) 2012-08-10
CA2746058C (en) 2016-05-17
EP2376499A1 (en) 2011-10-19
BRPI0922736B1 (pt) 2022-02-22
MX2011006206A (es) 2011-07-20
BRPI0922736A8 (pt) 2021-11-09
HRP20150428T1 (xx) 2015-06-19
TW201028426A (en) 2010-08-01
SG171907A1 (en) 2011-07-28
WO2010068181A1 (en) 2010-06-17
JP5669748B2 (ja) 2015-02-12
US9624242B2 (en) 2017-04-18
KR101729918B1 (ko) 2017-04-25
CN102282148B (zh) 2014-12-24
AR074724A1 (es) 2011-02-09
RU2527970C2 (ru) 2014-09-10
PL2376499T3 (pl) 2015-07-31
DK2376499T3 (en) 2015-05-04
IL213418A0 (en) 2011-07-31
US20150322084A1 (en) 2015-11-12
AU2009325147A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
CY2018024I2 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
NO2017026I1 (no) Alectinib (9-etyl-6,6-dimetyl-8-(4-morfolin-4-yl-piperidin-1-yl)-11-okso-6,11-dihydro-5H-benzo[b]-karbasol-3-karbonitril) eller salt eller solvat derav. (krav 1 i patentet)
BRPI1006113A2 (pt) &#34;derivado de piridina&#34;.
BRPI0923047A2 (pt) &#34;conjugados de proteínas-oligossacarídeos&#34;.
BRPI1011414A8 (pt) &#34;método.&#34;
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ITSA20100009U1 (it) Apparato per l&#39;alimentazione.
BRPI0923732A2 (pt) &#34;regeneração de catalisador&#34;.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
IT1397968B1 (it) Composizione pesticida acquosa.
BR112012000750A2 (pt) &#34;sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno&#34;
HRP20150413T8 (xx) 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.31.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen maleatna sol
EP2264029A4 (en) 1,3-dihydroisobenzofuran DERIVATIVE
BRPI0907749A2 (pt) Derivados de 3,8-diaminotetrahidroquinolina
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
NL2003140A1 (nl) Landbouwmachine.
NL2003137A1 (nl) Landbouwmachine.
CL2008000598A1 (es) Procedimiento de preparacion de 3-metil-4-fenilisoxazolo [3,4-d]piridazin-7(6h)-ona.
BRPI0918503A2 (pt) processo de preparação da 1,6:2,3-dianidro-beta-d-manopiranose
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
DE602007008319D1 (de) I.S.-Gerät

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CELL THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: CTI BIOPHARMA CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.